5:22 PM
 | 
Oct 29, 2012
 |  BC Extra  |  Company News

FDA grants Priority Review to regorafenib NDA for GIST

Bayer AG (Xetra:BAYN) and partner Onyx Pharmaceuticals Inc. (NASDAQ:ONXX) said FDA accepted for review and granted Priority Review to an NDA for regorafenib to treat metastatic...

Read the full 118 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >